Precision reagents for MEN2-associated mutant RET and next-generation TKI development targeting solvent front and gatekeeper resistance.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RET Y791F drug discovery. Below table lists available components:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Primary Target (Mutant) | RET Y791F Recombinant Kinase Domain. Active mutant protein, Tyr791Phe substitution. >95% purity. Sequence Verified. Theoretical MW: ~32 kDa (GST-fusion available). Endotoxin <1EU/µg. | View RET Y791F Products |
| Selectivity Control | RET Wild-Type (WT) Kinase Domain. Human WT kinase for selectivity profiling vs. oncogenic mutants. Endotoxin <1EU/µg. | View RET Products |
| Solvent Front Mutant | RET G810R Mutant Protein. Primary resistance mutation to 1st-gen inhibitors. Critical for next-gen TKI screening. | View RET G810R Products |
| Gatekeeper Mutant | RET V804M Mutant Protein. Classic steric hindrance mutation (V804M/L). Essential for ATP-pocket profiling. | View RET V804M Products |
| Additional Mutant | RET Y806C Mutant Protein. Affects activation loop stability; relevant for resistance profiling. | View RET Y806C Products |
| Fusion Oncogene | CCDC6-RET Fusion Protein. NSCLC-relevant rearrangement. Full kinase domain integrity preserved. | View CCDC6-RET Products |
| Gene Delivery | RET Y791F Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. | View RET Y791F Products |
| Benchmark Ab/Tool | Anti-RET Antibody / Inhibitor Control. Recombinant positive control for benchmark assays. | View RET Y791F Products |
| Validator | RET siRNA Set (Pool of 3). Knockdown control for fusion and mutant specificity. | View RET Products |
| Related Target | NTRK1 Kinase (WT/Mutant). Off-target liability screening for multi-kinase inhibitors. | View NTRK1 Products |
| Related Target | EGFR T790M Mutant. Common co-mutation in NSCLC; resistance profiling. | View EGFR T790M Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Discriminating Y791F constitutive activity from WT baseline | Paired WT/Y791F proteins with validated auto-phosphorylation capacity; ATP-binding site integrity confirmed |
| Resistance mutation profiling (G810R, V804M, Y806C) | Single-amino-acid substitution mutants with >95% purity; Mass spectrometry verified exact mutation |
| Selectivity vs. off-target kinases (NTRK, FGFR, EGFR) | Ortholog panel: RET, NTRK1/2/3, FGFR1, EGFR WT/mutants with sequence-verified ATP pockets |
| Fusion protein conformational integrity | Native linker sequence preservation in CCDC6-RET and KIF5B-RET constructs |
| Kinase Activity Validation | Active kinase domains strictly verified by mass spec and Theoretical MW |
| Lack of Controls | Clinical Benchmark tools included for accurate IC50 determination |
| False Positives | Validated siRNA included for specificity checks in cell lines |
Live RET Y791F R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RET-targeted therapeutics has shifted from first-generation pan-kinase inhibitors (Cabozantinib, Vandetanib) to highly selective TKIs (Selpercatinib, Pralsetinib). However, acquired and germline mutations such as Y791F (often associated with Medullary Thyroid Carcinoma and MEN2A) drive the need for next-generation inhibitors. The clinical emergence of acquired resistance mutations—particularly at the solvent front (G810R/S) and gatekeeper (V804L/M)—is driving R&D toward next-generation inhibitors capable of overcoming these steric and affinity barriers. As first-generation therapies reach the clinic and establish baseline efficacy, the next wave of R&D is heavily focused on overcoming specific resistance mutations, minimizing off-target VEGFR2 toxicity, and exploring Targeted Protein Degradation (PROTACs). RET Y791F, a constitutively active tyrosine kinase domain mutation, requires precision selectivity profiling against WT RET to minimize toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective TKI (1st Gen) | Eli Lilly (Selpercatinib), Roche (Pralsetinib) | RET-fusion NSCLC, MTC | Mutant vs. WT selectivity (Need purified Y791F & WT proteins) |
| Next-Gen TKI | Blueprint, Turning Point (BMS) | G810R/V804M Resistant MTC | Resistance mutant panel (Need G810R, V804M, Y806C proteins) |
| PROTACs (Degraders) | Emerging Biotechs (e.g., C4 Therapeutics) | Refractory Solid Tumors | Ternary Complex Validation (Need intact fusion protein or full-length RET) |
| Bispecific Antibodies | Preclinical stage | Advanced Cancers | Binding Assays (Need Sequence Verified ECDs) |